CMS Policy Sets Boundaries On Transcatheter Valve Procedure
Final Coverage Plan Includes Compromise, But Maintains Evidence Development, Other Restrictions
This article was originally published in The Gray Sheet
New Medicare coverage policy for transcatheter aortic valve replacement is a significant step for the nascent procedure and a possible window into how the agency will address future high-profile, early-stage technologies.
You may also be interested in...
A proposed update to the 2012 National Coverage Policy for transcatheter aortic valve replacement (TAVR) would make it easier for hospitals to begin a TAVR program while slightly raising the procedure-volume requirements for maintaining a continuing TAVR program. The agency believes the new rules would balance the need to expand patient access to TAVR while ensuring the quality and safety of TAVR procedures covered by Medicare.
CMS will consider a national policy for the left atrial appendage closure device in response to a request from Boston Scientific.
As FDA touts plans to shift clinical data requirements when possible to the postmarket phase, a top CMS official highlights the importance of the Medicare coverage with evidence development policy.